A team of researchers has reported an important advance in the search for better treatments for advanced prostate cancer.
Instead of simply shrinking tumors, the experimental medicine appears to attack two of cancer's greatest strengths at the same time.
It reduces the growth of the original tumor while also blocking its ability to spread throughout the body. Scientists say this approach could eventually lead to better outcomes for patients with aggressive disease.
Prostate cancer affects millions of men worldwide. While many cases can be successfully treated or carefully monitored, aggressive forms remain a major medical challenge.
These cancers can spread beyond the prostate to the bones and lymph nodes, causing pain, disability, and making treatment much more difficult. Finding ways to stop metastasis has therefore become one of the highest priorities in prostate cancer research.
The new treatment was created by researchers at Umeå University working with international collaborators.
They developed a fully human antibody, a specially designed protein that attaches to a specific target involved in cancer growth. Because it is fully human, the antibody is expected to be suitable for use as a medicine if future testing proves it is safe and effective.
During preclinical experiments, the antibody achieved encouraging results. It slowed the growth of aggressive prostate tumors and prevented the formation of metastatic tumors. Researchers also identified the biological pathways responsible for these effects, providing stronger evidence that the treatment is working exactly as intended rather than by chance.
Another promising feature is that the medicine works differently from existing treatments. By targeting a new pathway involved in cancer development, it may offer benefits for patients whose cancers no longer respond well to current drugs.
Scientists also hope that its unique design could reduce some treatment-related side effects, although this must still be confirmed in future studies.
The researchers say their long-term goal is not only to improve survival but also to improve quality of life for men living with advanced prostate cancer. They are already planning additional research to determine whether the same antibody might also be effective against other types of solid cancers.
Experts caution that patients should not expect the treatment to become available immediately. Developing a new medicine is a lengthy process involving extensive safety testing, clinical trials in people, and careful review by health authorities before approval can be granted.
The study was published in Signal Transduction and Targeted Therapy.
Overall, these findings are encouraging because the treatment targets both tumor growth and the spread of cancer, two major challenges in advanced prostate cancer. The study was carried out in preclinical models, so the results do not yet prove that the drug will work safely or effectively in people.
More laboratory testing, human clinical trials, and approval from health regulators will be required before patients can receive the treatment. Even so, the research represents an important early step toward developing a new type of targeted cancer therapy that may improve survival and quality of life for people with aggressive prostate cancer.
If you care about prostate cancer, please read studies about a natural ally against prostate cancer, and supplements and keto diet can boost immunotherapy for prostate cancer.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and low-fat diet may help stop cancer growth.
Source: Umeå University. Credit: Unsplash+
A team of researchers has reported an important advance in the search for better treatments for advanced prostate cancer.
Instead of simply shrinking tumors, the experimental medicine appears to attack two of cancer’s greatest strengths at the same time.
It reduces the growth of the original tumor while also blocking its ability to spread throughout the body. Scientists say this approach could eventually lead to better outcomes for patients with aggressive disease.
Prostate cancer affects millions of men worldwide. While many cases can be successfully treated or carefully monitored, aggressive forms remain a major medical challenge.
These cancers can spread beyond the prostate to the bones and lymph nodes, causing pain, disability, and making treatment much more difficult. Finding ways to stop metastasis has therefore become one of the highest priorities in prostate cancer research.
The new treatment was created by researchers at Umeå University working with international collaborators.
They developed a fully human antibody, a specially designed protein that attaches to a specific target involved in cancer growth. Because it is fully human, the antibody is expected to be suitable for use as a medicine if future testing proves it is safe and effective.
During preclinical experiments, the antibody achieved encouraging results. It slowed the growth of aggressive prostate tumors and prevented the formation of metastatic tumors. Researchers also identified the biological pathways responsible for these effects, providing stronger evidence that the treatment is working exactly as intended rather than by chance.
Another promising feature is that the medicine works differently from existing treatments. By targeting a new pathway involved in cancer development, it may offer benefits for patients whose cancers no longer respond well to current drugs.
Scientists also hope that its unique design could reduce some treatment-related side effects, although this must still be confirmed in future studies.
The researchers say their long-term goal is not only to improve survival but also to improve quality of life for men living with advanced prostate cancer. They are already planning additional research to determine whether the same antibody might also be effective against other types of solid cancers.
Experts caution that patients should not expect the treatment to become available immediately. Developing a new medicine is a lengthy process involving extensive safety testing, clinical trials in people, and careful review by health authorities before approval can be granted.
The study was published in Signal Transduction and Targeted Therapy.
Overall, these findings are encouraging because the treatment targets both tumor growth and the spread of cancer, two major challenges in advanced prostate cancer. The study was carried out in preclinical models, so the results do not yet prove that the drug will work safely or effectively in people.
More laboratory testing, human clinical trials, and approval from health regulators will be required before patients can receive the treatment. Even so, the research represents an important early step toward developing a new type of targeted cancer therapy that may improve survival and quality of life for people with aggressive prostate cancer.
